People with Parkinson's disease gain more daily hours without dyskinesia with subcutaneous infusion of a levodopa–carbidopa solution than with oral levodopa–carbidopa.
NLY01, a modified version of the glucagon-like peptide-1 receptor agonist exenatide, showed no motor or nonmotor benefits in patients with Parkinson’s disease in a phase 2 trial.
Circadian changes may drive neurodegeneration, as well as causing some of the sleep–wake symptoms in Parkinson’s disease. This review explores approaches to target sleep and chronobiology as a novel treatment strategy.
Our tailored content service will keep you up to date…
Receive newsletters curated for the busy specialist by our expert editorial team
Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
A 38-year-old man developed early-onset Parkinson's disease after regularly using 3,4-methylenedioxymethamphetamine (MDMA), and went on to use methamphetamines to alleviate his disease symptoms, potentially perpetuating the disease process.
Neurodegenerative diseases cause progressive deterioration in cognitive function by the loss of the activity of neurons in the brain. Worldwide, 10.2 million people suffer from neurodegenerative disorders, and the incidence is steadily increasing.
Parkinson’s disease (PD) is the second most common progressive neurodegenerative condition. The disease was first described in the 19 th century [ 1 ] and is clinically characterized by asymmetric-onset tremor, bradykinesia, rigidity, and postural …
Open AccessDeep Brain StimulationNeurology and Preclinical Neurological Studies - Review Article
Device aided therapies (DAT) comprising the intrajejunal administration of levodopa/carbidopa intestinal gel (LCIG) and levodopa/carbidopa/entacapone intestinal gel (LECIG), the continuous subcutaneous application of foslevodopa/foscarbidopa or …
Open AccessParkinson's DiseaseNeurology and Preclinical Neurological Studies - Review Article
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by progressive degeneration of dopaminergic neurons in the substantia nigra and other brain regions. A key pathological feature of PD is the abnormal accumulation of …
Neuroimaging plays an increasingly critical role in clinical practice. PET Pearls is an interactive activity designed to improve your confidence and accuracy when interpreting imaging for early signs of cognitive impairment.
STEM-PD, the first in-human safety trial of stem cell therapy for Parkinson’s disease, began this year and marks a huge step forward for this type of treatment.
We talk to Prof. Malin Parmar about why stem cell therapy is such a good option for patients with Parkinson’s disease and get an update on the current status of the trial.
Subthalamic deep brain stimulation (STN-DBS) is known to improve motor function in advanced Parkinson’s disease (PD) and to enable a reduction of anti-parkinsonian medication. While the levodopa challenge test and disease duration are considered …
Open AccessParkinson's DiseaseNeurology and Preclinical Neurological Studies - Original Article
Urinary symptoms are frequent in Parkinson’s disease (PD), with patients experiencing both storage and voiding difficulties, such as urgency, incontinence, polyuria, nicturia and voiding hesitancy (Chaudhuri and Schapira 2009 ; Picillo et al. 2017 …
Asymmetry of motor symptoms is characteristic for Parkinson’s disease (PD) and is particularly observed in the early disease stages. However, asymmetry of symptoms is thought to persist during the entire course of the disease, even if to a lesser …
Neurodegenerative diseases cause progressive deterioration in cognitive function by the loss of the activity of neurons in the brain. Worldwide, 10.2 million people suffer from neurodegenerative disorders, and the incidence is steadily increasing.
